Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

NCT01486446 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Erythromelalgia
Inherited Erythromelalgia

Interventions

DRUG: XPF-002
DRUG: Placebo

Sponsor

Xenon Pharmaceuticals Inc.